Genomic alterations in salivary gland carcinomas: an illustrated update
Genomic alterations in salivary gland carcinomas: an illustrated update
Since the publication of our review on genomic alterations in salivary gland tumours in Diagnostic Histopathology in 2020, there have been several major developments. In the United Kingdom, next generation sequencing (NGS) of several tumour types is now commissioned by the National Health Service (NHS) either by whole genome sequencing (WGS) of fresh tumours, or targeted NGS in formalin-fixed paraffin embedded (FFPE) tissue. The UK genomic test directory includes several key gene fusion tests in salivary tumours, including NTRK, MAML2, EWSR1 and MYB. These can aid the clinician not only in refining histopathological classification in challenging cases, but they also have important therapeutic implications for patients with recurrent disease or where standard-of-care management options have been exhausted. This review will provide a brief update, including newly described entities since the previous review (most notably microsecretory carcinoma), as well as illustrating the utility of genomic testing in salivary tumours using several recent examples from our clinical practice.
genomic medicine, molecular diagnostics, salivary pathology
249-252
Moutasim, Karwan A.
af7dd711-f6df-44f7-8c57-052bf15303af
Thomas, Gareth J.
2ff54aa9-a766-416b-91ee-cf1c5be74106
28 April 2022
Moutasim, Karwan A.
af7dd711-f6df-44f7-8c57-052bf15303af
Thomas, Gareth J.
2ff54aa9-a766-416b-91ee-cf1c5be74106
Moutasim, Karwan A. and Thomas, Gareth J.
(2022)
Genomic alterations in salivary gland carcinomas: an illustrated update.
Diagnostic Histopathology, 28 (5), .
(doi:10.1016/j.mpdhp.2022.02.005).
Abstract
Since the publication of our review on genomic alterations in salivary gland tumours in Diagnostic Histopathology in 2020, there have been several major developments. In the United Kingdom, next generation sequencing (NGS) of several tumour types is now commissioned by the National Health Service (NHS) either by whole genome sequencing (WGS) of fresh tumours, or targeted NGS in formalin-fixed paraffin embedded (FFPE) tissue. The UK genomic test directory includes several key gene fusion tests in salivary tumours, including NTRK, MAML2, EWSR1 and MYB. These can aid the clinician not only in refining histopathological classification in challenging cases, but they also have important therapeutic implications for patients with recurrent disease or where standard-of-care management options have been exhausted. This review will provide a brief update, including newly described entities since the previous review (most notably microsecretory carcinoma), as well as illustrating the utility of genomic testing in salivary tumours using several recent examples from our clinical practice.
Text
Moutasim & Thomas_Salivary gland tumours review - 2022 Updated 17012022
- Accepted Manuscript
Restricted to Repository staff only
Request a copy
Text
1-s2.0-S1756231722000330-main
- Version of Record
Restricted to Repository staff only
Request a copy
More information
e-pub ahead of print date: 19 March 2022
Published date: 28 April 2022
Additional Information:
Publisher Copyright:
© 2022
Copyright:
Copyright 2022 Elsevier B.V., All rights reserved.
Keywords:
genomic medicine, molecular diagnostics, salivary pathology
Identifiers
Local EPrints ID: 456920
URI: http://eprints.soton.ac.uk/id/eprint/456920
ISSN: 1756-2317
PURE UUID: 62569fd4-b623-4877-969f-ec6f22b42942
Catalogue record
Date deposited: 17 May 2022 16:41
Last modified: 16 Mar 2024 17:03
Export record
Altmetrics
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics